Numerous research ideas have been borne during the management of our poisoned patients. We have also collaborated with other institutions to perform multi-center research groups. The following are research projects recently completed or in process:
Recently the Division of Medical Toxicology participated in a multi-center study of antivenom for Black Widow Spider bites.
Researched Abuse, Diversion, and Addiction Related-Related Surveillance (RADARs). Study sponsor: Purdue Pharma. Ongoing.
Stanford CF, Schaeffer TH, Delgado J, Holstege CP, Olsen D, Bogdan GM, Heard K. Treatment of life threatening digoxin toxicity with digoxin immune FAB. NACCT 2007.
Stanford CF, Bebarta V, Holstege CP, Bush SP, Richardson WH, Olsen D, Dart RC. Is Crotaline fab antivenom efficacious for severe envenomations (abstract)? NACCT 2007.
Stanford CF, Bush SP, Clark RF, Arnold TA, Holstege CP, Haynes J, Bogdan GM, Garcia W, Dart RC. A new FAB2 antivenom for widow spider envenomation (latrodectism). NACCT 2007.
Reilly T, Holstege CP, Kirk MA. Material Safety Data Sheet (MSDS) Inconsistencies Pertaining to N, N diethyl-m-toluamide (DEET). Clin Toxicol 2006;44(5):771. NACCT 2006.
Holstege CP, Brady W, Baer AB, Eldridge DL. The association of cardiovascular toxins and electrocardiographic abnormality in poisoned patients. J Toxicol Clin Toxicol 2005;43(5):504. NACCT 2005.
- Rowden AK, Buck ML, Eldridge DL, Holstege CP. The radiopacity
of ingested transdermal medicinal patches in a simulated human
model. J Toxicol Clin Toxicol 2005;43(6):695. NACCT 2005.
- Michels JE, Blizzard JC, Holstege CP, Richardson W. Cost-benefit analysis of poison center phone services. Clin Toxicol. 2006;44(5):669. NACCT 2006